Life sciences firms are reevaluating their approach to liability as they move from clinical trials to commercialization. The transition brings new challenges, with risks evolving in complexity rather than just increasing in scale. Industry experts highlight that early-stage risks, such as those linked to clinical trials and intellectual property, are no longer the primary concern.
As organizations expand into full-scale production and market distribution, they face new legal and regulatory hurdles. These include product liability, compliance with ongoing regulations, and managing public perception. Jennifer Ampulski, an industry expert, explains that the nature of risks changes significantly during this phase.
The shift requires companies to adapt their risk management strategies. This includes strengthening internal controls, engaging with regulators, and preparing for potential lawsuits. The evolving landscape underscores the need for continuous reassessment of legal exposure throughout the product lifecycle.
With more products entering the market, the focus is now on long-term risk mitigation. Companies are investing in robust compliance frameworks and legal support to navigate the complexities of commercialization. This transition marks a critical phase in the life sciences industry.
